Nanobac Pharmaceuticals Inc. To Begin Domestic Manufacturing of
Diagnostic Tests
Thursday August 16, 8:00 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP
- News; "Nanobac" or "the Company") announces that its proprietary CE
marked Nano-Capture ELISA assay and Nano-Sero IgG ELISA assay
currently manufactured by the Company's subsidiary in Kuopio, Finland,
will be made in the United States for use in clinical trials, FDA
approval and expanded distribution.
The Company's diagnostics detect Calcifying Nano Particles (CNPs)
which are linked to several diseases associated with pathologic
calcification. The Company believes that its diagnostics will serve as
biomarkers allowing for earlier identification, diagnosis, and
treatment of such diseases.
"The technology transfer of our proprietary diagnostic to a FDA
approved U.S. manufacturing facility is a hallmark event for our
company," commented Dr. Benedict Maniscalco, Nanobac's Co-Chair and
Chief Medical Officer. "Bringing our manufacturing to the United
States will potentially allow us to make our diagnostic a standard of
care in U.S. Healthcare and represents a key step to transition from a
research oriented company to one that rapidly develops products for
sales and marketing worldwide."
For more information on the Company's direction please refer to the
Investor Section at nanobac.com . Further, for frequent
updates on Nanobac's progress please register as a friend of Nanobac
at nanobac.com .
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For
more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals Inc., Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc. |
